8-K: 10x Genomics Reports Mixed Q4 and Full Year 2024 Results, Provides Cautious 2025 Outlook

10x Genomics reported a decrease in revenue for both Q4 and full year 2024, while launching the Billion Cells Project and providing a modest revenue growth outlook for 2025.

Summary

• 10x Genomics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 revenue was $165.0 million, a 10% decrease compared to the same period in 2023.
• Full year 2024 revenue was $610.8 million, a 1% decrease compared to 2023.
• Gross margin for Q4 2024 was 67%, up from 63% in the prior year period, driven by product mix changes.
• Gross margin for full year 2024 was 68%, compared to 66% in 2023.
• Operating expenses decreased by 6% in Q4 and 10% for the full year, primarily due to lower research and development expenses.
• The company's operating loss was $49.8 million for Q4 and $194.6 million for the full year.
• Net loss was $49.0 million for Q4 and $182.6 million for the full year.
• Cash and cash equivalents and marketable securities totaled $393.4 million as of December 31, 2024.
• 10x Genomics expects full year 2025 revenue to be in the range of $610 million to $630 million, representing 0% to 3% growth.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is experiencing revenue declines, it is also improving gross margins and reducing operating expenses. The 2025 outlook is cautiously optimistic.

Positives

• Gross margin improved in both Q4 and full year 2024.
• Operating expenses decreased, leading to a smaller operating loss compared to the previous year.
• The company launched major new products across all three platforms in 2024.
• 10x Genomics is collaborating with CZI and Ultima Genomics on the Billion Cells Project.
• Cash reserves remain strong at $393.4 million.

Negatives

• Revenue decreased by 10% in Q4 and 1% for the full year.
• The company experienced an operating loss of $49.8 million for Q4 and $194.6 million for the full year.
• Net losses were $49.0 million for Q4 and $182.6 million for the full year.
• The company faces uncertainty within U.S. academic research.

Risks

• Uncertainty within U.S. academic research could impact future revenue.
• The company's ability to achieve its 2025 revenue guidance is subject to market conditions and execution risks.
• Competition in the single cell and spatial biology market could impact market share and profitability.
• The company's reliance on research and development could impact future growth if projects are not successful.

Future Outlook

10x Genomics expects full year 2025 revenue to be in the range of $610 million to $630 million, representing 0% to 3% growth over full year 2024. The midpoint of this guidance implies double-digit growth for both Chromium reactions and overall spatial revenue.

Management Comments

• Serge Saxonov, Co-founder and CEO, stated that the company launched major new products and made changes to its commercial organization and go-to-market strategy in 2024.
• Saxonov expressed strong conviction in the large opportunity ahead despite current uncertainty within U.S. academic research.
• Saxonov stated that the company's goal for 2025 is to take advantage of the changes made in 2024 and deliver consistent execution.

Industry Context

10x Genomics operates in the rapidly evolving single cell and spatial biology market. The collaboration with CZI and Ultima Genomics on the Billion Cells Project highlights the increasing importance of large datasets and AI in biological research. The company's focus on new product launches and commercial strategy adjustments reflects the competitive landscape and the need to adapt to changing market conditions.

Comparison to Industry Standards

• Competitors like Illumina and Bio-Rad also operate in the genomics and life science tools market.
• Illumina, a leader in DNA sequencing, reported revenue of $4.5 billion in 2023, demonstrating the scale of the genomics market.
• Bio-Rad, another key player, reported sales of $2.8 billion in 2023, highlighting the diverse range of products and services in the industry.
• 10x Genomics' focus on single cell and spatial biology positions it in a high-growth segment, but it faces competition from companies with broader product portfolios.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and operating losses.
• Employees may be affected by the restructuring of the commercial organization.
• Customers may benefit from the new product launches and technological advancements.
• Suppliers may experience changes in demand based on the company's performance.

Next Steps

• The company will host a conference call to discuss the fourth quarter and full year 2024 financial results, business developments and outlook.
• Management aims to deliver consistent execution in 2025 by leveraging changes made to the commercial organization and go-to-market strategy.

Key Dates